https://www.selleckchem.com/products/AZD0530.html
an trial. This study is the first in human for Miltuximab® a first in class antibody targeting GPC-1. The trial met its primary endpoint of safety, demonstrating its potential as a safe and tolerable monoclonal antibody. This safety data, together with targeting to tumour lesions and biodistribution information supports the further clinical development of Miltuximab® as a theranostic agent in a planned Phase I human trial. To assess respiratory-gated (RG) positron emission tomography (PET) acquisition for patients with liver metastases
Like
Comment
Share
